Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UrologixULGX Days Payable is 50.45 as of Mar. 2015.
Urologix's average Accounts Payable for the
three
months ended in Mar. 2015 was $0.82 Mil. Urologix's Cost of Goods Sold for the
three
months ended in Mar. 2015 was $1.49 Mil.
Hence, Urologix's Days Payable for the
three
months ended in Mar. 2015 was 50.45.
The historical rank and industry rank for Urologix's Days Payable or its related term are showing as below:
ULGX's Days Payable is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 68.6 * Ranked among companies with meaningful Days Payable only.
Urologix's Days Payable
increased
from Mar. 2014 (37.65) to Mar. 2015 (50.45).
It may suggest that Urologixdelayed paying its suppliers.
The historical data trend for Urologix's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Urologix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Urologix Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Days Payable distribution charts can be found below:
* The bar in red indicates where Urologix's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Urologix's Days Payable for the fiscal year that ended in Jun. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Urologix (ULGX) has a Days Payable of 50.45 as of Mar. 2015. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Urologix and its competitors.
Is Urologix's Days Payable too high?
Urologix's current Days Payable is 50.45. The Medical Devices & Instruments industry median Days Payable is 68.60. Urologix's value of 50.45 is 26.5% below this industry median.
How does Urologix's Days Payable compare to MFST and GTHP?
Urologix's Days Payable of 50.45 can be compared against companies in the Medical Devices & Instruments industry. The industry median Days Payable is 68.60. Urologix's value of 50.45 is 26.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.60, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Urologix's current Days Payable of 50.45 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Urologix and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Urologix's current Days Payable is 50.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Urologix stock overvalued right now?
Urologix (ULGX) has a current Days Payable of 50.45. The current Days Payable is 50.45 and 26.5% below the Medical Devices & Instruments industry median of 68.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Urologix (ULGX), the current Days Payable is 50.45 as of Mar. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ULGX has been successfully added to your 
